In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy by Weiswald, Louis-Bastien et al.
TECHNICAL ADVANCE Open Access
In situ protein expression in tumour spheres:
development of an immunostaining protocol for
confocal microscopy
Louis-Bastien Weiswald
1, Jean-Marc Guinebretière
2, Sophie Richon
1, Dominique Bellet
1,3, Bruno Saubaméa
4†,
Virginie Dangles-Marie
1,5*†
Abstract
Background: Multicellular tumour sphere models have been shown to closely mimic phenotype characteristics of
in vivo solid tumours, or to allow in vitro propagation of cancer stem cells (CSCs). CSCs are usually characterized by
the expression of specific membrane markers using flow cytometry (FC) after enzymatic dissociation. Consequently,
the spatial location of positive cells within spheres is not documented. Confocal microscopy is the best technique
for the imaging of thick biological specimens after multi-labelling but suffers from poor antibody penetration. Thus,
we describe here a new protocol for in situ confocal imaging of protein expression in intact spheroids.
Methods: Protein expression in whole spheroids (150 μm in diameter) from two human colon cancer cell lines,
HT29 and CT320X6, has been investigated with confocal immunostaining, then compared with profiles obtained
through paraffin immunohistochemistry (pIHC) and FC. Target antigens, relevant for colon cancer and with
different expression patterns, have been studied.
Results: We first demonstrate that our procedure overcomes the well-known problem of antibody penetration in
compact structures by performing immunostaining of EpCAM, a membrane protein expressed by all cells within
our spheroids. EpCAM expression is detected in all cells, even the deepest ones. Likewise, antibody access is
confirmed with CK20 and CD44 immunostaining. Confocal imaging shows that 100% of cells express b-catenin,
mainly present in the plasma membrane with also cytoplasmic and nuclear staining, in agreement with FC and
pIHC data. pIHC and confocal imaging show similar CA 19-9 cytoplasmic and membranar expression profile in a
cell subpopulation. CA 19-9
+ cell count confirms confocal imaging as a highly sensitive method (75%, 62% and
51%, for FC, confocal imaging and pIHC, respectively). Finally, confocal imaging reveals that the weak expression of
CD133, a putative colon CSC marker, is restricted to the luminal cell surface of colorectal cancer acini, with CD133
+
cellular debris into glandular lumina.
Conclusion: The present protocol enables in situ visualization of protein expression in compact three-dimensional
models by whole mount confocal imaging, allowing the accurate localization and quantification of cells expressing
specific markers. It should prove useful to study rare events like CSCs within tumour spheres.
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In a constant effort to produce more and more perti-
nent in vitro models for cancer studies, the importance
of studying cancer cells in three-dimensions (3D) is
increasingly recognized [1-5]. For this purpose, spher-
oids can be produced in vitro with some permanent
cancer cell lines, including colon cancer cell lines, when
cultured in non-adherent conditions [6,7]. These spher-
oids are known to mimic microtumours more closely
than cancer cell line monolayers and have been mainly
used in chemo- and radio-resistance studies. Indeed,
tumour spheroids represent quite realistically the three-
dimensional growth and organization of solid avascular
tumours and, consequently, simulate much more pre-
cisely the cell-cell interactions and microenvironmental
conditions found in tumours, especially nutrient and
oxygen gradients. Another 3D cancer cell model, requir-
ing a specific culture protocol, aims to promoting in
vitro expansion of cancer stem cells (CSCs) from solid
tumour tissue as is the case with neurospheres [8,9],
mammospheres [10,11] or colon cancer spheres [12,13].
CSCs are defined as a rare subset of tumour cells, which
have the unique capability to form tumours in serial
xenotransplantation assays, and to reestablish, at each in
vivo passage, the hierarchical cell organization and het-
erogeneity of the parental tumour. In vitro methods
have been developed to grow and study these cells in
sphere-forming assays. The phenotypic cell isolation
strategy that relies on the immunotargeting of cell sur-
face proteins coupled with cell sorting by flow cytometry
(FC) is now widely used to isolate CSCs, after enzymatic
dissociation of tumour samples or cancer spheres.
Up to now, protein expression by these sphere form-
ing cells was mostly studied by FC on single cells.
Immunostaining techniques performed on the whole
intact spheres are traditionally done on cytospin pre-
parations [14,15] and paraffin [16,17] or frozen sections
[13,17] because of the common failure of the antibodies
to penetrate fully into compact tumour spheres, leading
to a loss of information. Besides, the cytospin approach
is limited to the investigation of the more external cells,
while physical sections do not allow the analysis of the
entire 3D structure, unless time-consuming serial sec-
tioning is performed. Another way to gain access to the
whole structure has been to use confocal imaging of
three dimensional tumour spheroids expressing geneti-
cally encoded fluorescent reporters fused to the proteins
of interest [18,19]. However, this approach requires a
cell transfection step and does not allow visualizing
endogenous proteins at their physiological levels.
In the present work, we describe a new immunostain-
ing protocol in which spheroids are simultaneously fixed
and permeabilized in a mixture of paraformaldehyde
and Triton X100 and then gradually dehydrated in
methanol before incubation with labelling antibodies.
We show that this results in the complete permeabiliza-
tion of the spheroids while preserving their structures
and the localization of the proteins of interest. Whole
spheroids can then be imaged in the confocal micro-
scope to reveal the spatial distribution patterns of
several endogenous proteins in situ.
Methods
Cell culture
CT320X6, established in the laboratory [20], and HT29
(ATCC, HTB-38) colon cancer cell lines were main-
tained in DMEM supplemented with 10% FCS, 10
mmol/L HEPES, 4.5 g/L glucose, 1 mol/L pyruvate
sodium, 200 units/mL penicillin, 200 μg/mL streptomy-
cin at 37°C, with 8% CO2.
Three-dimensional multicellular spheroids were pre-
pared by the liquid overlay technique [6]. In brief, tissue
culture microplates were coated with 75 μlo f1 %a g a r -
ose in water. CT320X6 and HT29 cells grown as a two-
dimensional monolayer were resuspended with trypsin,
and 2 × 10
3 (CT320X6) or 1 × 10
3 (HT29) cells were
seeded in 150 μl of culture medium to obtain a single
spheroid per microwell with a diameter between 120
and 150 μm after 4 days.
Antibodies
Primary antibodies used for flow cytometry, paraffin
immunohistochemistry and confocal microscopy are
recapitulated in Table 1. AlexaFluor®488 conjugated goat
anti-mouse and AlexaFluor®555 conjugated goat anti-
rabbit secondary antibodies were from Invitrogen (Cergy
Pontoise, France). The results shown in all figures are
from one experiment taken as representative of at least
three independent experiments.
Flow cytometry analysis
Spheroids were disaggregated with trypsin (0.025%)/
EDTA (2 mmol/L) and cell concentration was adjusted
to 1 × 10
6 cells/ml with DMEM supplemented with 10
mmol/L HEPES, 4.5 g/L glucose, 1 mmol/L pyruvate
sodium.
For EpCAM, CD44 and CD133 staining, living cells
were incubated for 30 minutes at 4°C with primary
antibody and eventually followed by anti-mouse Alexa-
Fluor®488 secondary antibody (30 min at 4°C). CK20,
b-catenin and CA 19-9 staining was performed after cell
fixation and permeabilization using Intrastain kit
(DAKO, Trappes, France) according to the instructions
of the manufacturer.
Labelled cells were analyzed by an Epics XL cytometer
(Coulter, Villepinte, France) and data were computed
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Research Institute, La Jolla, CA, USA). Gating was done
on the basis of negative-control staining profiles,
obtained by substituting primary antibodies with isotypic
non immune IgGs.
Paraffin immunohistochemistry
Spheroids were embedded using the Cytoblock™ method
and the Shandon kit (Thermo electroncorporation, Saint
Herblay, France) [21]. Immunostaining was performed
using an automated immunostainer (Dako Autostainer,
Dako) with appropriate antibody dilution (see Table 1).
Dako REAL™ system (Dako) was used for antibody bind-
ing detection according to the manufacturer’s
instructions.
Confocal microscopy
Fixation/permeabilization
About 100 spheroids in suspension were fixed and per-
meabilized for 3 h at 4°C in phosphate buffered saline
(PBS) containing 4% PFA (Euromedex, Mundolsheim,
France) and 1% Triton X-100 (Perbio Science, Brébières,
France) and washed in PBS (3 × 10 min). Spheroids
were then dehydrated in an ascending series of metha-
nol at 4°C in PBS (25%, 50%, 75%, 95%, 30 min each
and 100% for 5 h), rehydrated in the same descending
series and washed in PBS (3 × 10 min).
Antibody staining
After blocking in PBST (0.1% Triton X-100 in PBS) con-
taining 3% Bovine Serum Albumin (MP Biomedicals, Ill-
kirch, France) overnight at 4°C and washing in PBST (2 ×
15 min), spheroids were incubated with primary antibodies
diluted in PBST on a gently rocking rotator at 4°C for 48 h
and rinsed in PBST (4 × 30 min). When necessary, spher-
oids were then incubated in appropriate AlexaFluor conju-
gated secondary antibodies for 24 h. Cell nuclei were
eventually counterstained by TOPRO-3 (Invitrogen)
diluted 1:500 in PBS for 40 min at room temperature.
Mounting
Mounting was carried out in a simple chamber
assembled from a glass slide and a cover slip, using dou-
ble-sided scotch as ‘spacer’ between them. Spheroids
were resuspended in 15 μl of PBS and allowed to adhere
on a SuperFrost glass slide (Roth, Karlsruhe, Germany).
After careful blotting of excess buffer, spheroids were
mounted in 15 μl of 90% glycerol (v/v in PBS) using 0.17
mm thick coverslips (Assistent, Sondheim, Germany).
Edges of the coverslip were sealed with nail polish.
Confocal image acquisition and analysis
Images were recorded on a Leica TCS SP2 confocal
microscope (Leica Microsystems, Wetzlar, Germany)
equipped with a 40× oil-immersion objective (NA =
1.32). The three channels were acquired sequentially
with the following excitation and emission parameters:
(488 nm, 500-540 nm) for Alexa 488 and FITC,
(543 nm, 555-615 nm) for Alexa 555 and (633 nm, 645-
750 nm) for TOPRO-3. Gains were adjusted to avoid
saturation in pixels intensity. The three channels were
merged using Image J software.
Negative controls, in which primary antibodies were
substituted with isotypic non immune IgGs, did not give
rise to any detectable labelling. No post-imaging treat-
ment was used except for TOPRO-3 images which were
systematically despeckled in Image J.
CA 19-9 and ALDH1 positive and negative cells
within a spheroid were manually counted using the Cell
Counter plug-in of the ImageJ software and the percen-
tage of positive cells was determined at a depth of 40
μma n d7 0μm relative to the coverslip. No significant
difference was observed between both depths within the
same spheroid. This analysis was performed for three
independent experiments from which mean and SD
values were determined.
3D reconstruction
For 3D reconstruction, a stack of confocal images
was collected through the spheroids with step size of
Table 1 Primary antibodies used in the study.
Antibody dilution
Targeted antigen Clone name Manufacturer Ab type
aFC
bpIHC Confocal imaging
Primary antibodies
Ep-CAM HEA-125 Miltenyi-Biotec SAS FITC-mouse IgG1 1:11 - 1:50
CK20 IT-Ks 20.10 Biovalley FITC-mouse IgG1 1:50 - 1:50
Beta-Catenin b-catenin-1 DAKO mouse IgG1 1:20 - 1:50
Beta-Catenin 14/Beta-Catenin BD Biosciences mouse IgG1 - 1:400 -
CA 19-9 C241:5:4:1 Novacastra mouse IgG1 1:20 1:200 1:50
CD133 AC133 Miltenyi-Biotec SAS mouse IgG1 1:11 - 1:50
EBP50 - Calbiochem rabbit
cpAb - - 1:300
CD44 G44-26 BD Biosciences mouse IgG2b 1:50 1:10 1:50
ALDH1 44/ALDH BD Biosciences mouse IgG1 - 1:100 1:100
aFC: flow cytometry;
bpIHC: paraffin immunochemistry;
cpAb: polyclonal antibody
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one pole of the spheroids. After thresholding, this stack
was used to generate a 3D animation sequence by using
the 3D Projection routine in Image J.
Statistical analysis
Percentage of positive cells detected by the different
techniques was compared pairwise using a Wilcoxon-
Mann-Whitney one-sided test. A p value of less than
0.05 was considered to be significant.
Results and discussion
The method presented here aims to visualizing in situ
the expression of proteins in three-dimensional tumour
models using immunostaining coupled with confocal
imaging. We used HT29 and CT320X6 colon cancer
cell lines because of their ability to form compact multi-
cellular tumour spheroids when cultured according to
the liquid overlay technique [6]. All spheroids used had
a diameter comprised between 120 and 150 μm.
One of the main problems arising in confocal imaging
of thick specimens is the poor penetration of the antibo-
dies within the whole structure. Therefore, we first
addressed this issue by performing confocal imaging
after immunostaining of the spheroids against a marker
expressed evenly by all cells within the spheroids. We
chose Epithelial Cell Adhesion Molecule (EpCAM), a
membrane protein also known as Epithelial-Specific
Antigen (ESA) since all cells of the HT29 and CT320X6
spheroids are known to be positive for EpCAM, as con-
firmed by FC analysis (Figure 1A). After immunostain-
ing with an anti-EpCAM monoclonal antibody
conjugated to FITC, confocal images were recorded in
single optical planes located 40 μma n d7 0μmb e l o w
the surface of the coverslip.
As explained below, the main problem we had to deal
with was the penetration of the antibody through the
whole spheroid. The fixation and permeabilization steps
appeared to be the most critical ones to achieve this
goal.
Figure 1 Homogeneous penetration of EpCAM-FITC antibody in whole spheroids. (A) Flow cytometry analysis of CT320X6 (left histogram)
and HT29 (right histogram) cells from dissociated spheroids. Cells were labelled with the same FITC-conjugated EpCAM antibody (red area) or
FITC-conjugated isotype control antibody (white area). All cells were EpCAM positive. (B) CT320X6 (left panels) and HT29 (right panels) spheroids
were fixed and permeabilized as described in Methods. Spheroids were then directly labelled using FITC-conjugated EpCAM antibody (yellow)
and counterstained with TOPRO-3 (cyan). Acquisitions were taken at 40 μm and 70 μm depth within the same spheroid (scale bar = 50 μm).
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PFA (3 h, 4°C) followed by permeabilization in 1%
Triton X100 (1 h, RT) did not yield satisfactory results.
This procedure resulted in a bright anti-EpCAM stain-
ing of cell plasma membranes in the periphery of the
spheroid but left the centre of the spheroid without any
detectable labelling (Additional file 1A). This was in
contrast to staining with TOPRO-3, a small cell-imper-
meant molecule, which stained all cell nuclei in the
spheroids. Changing the experimental conditions for the
fixation (2-4% PFA, 1-12 h, RT or 4°C) or the permeabi-
lization (0.5-3% Triton X100, 1-6 h, RT or 4°C), using
other detergents (saponine, SDS) or increasing incuba-
tion times in antibodies (up to 72 h) did not lead to any
improvement (data not shown). The reverse protocol
consisting in extraction (0.1% Triton X100, 5 min, 4°C)
prior to fixation (4% PFA, 3 h, 4°C) resulted in cell
membrane damage in the periphery of the spheroids
with seemingly no permeabilization in the centre (Addi-
tional file 1B). Simultaneous fixation/permeabilization in
a single step led to a striking increase of the staining
inside the spheroids with no apparent alteration of the
structure (Additional file 1C). Indeed, when spheroids
were incubated in PBS containing 4% PFA and 1%
Triton X-100 at 4°C for 3 h before immunostaining, all
cells were evenly labelled down to a depth of 40 μm.
However, the very center of the spheroid still appeared
devoided of any staining as evidenced in images taken at
70 μm depth (Additional file 1D).
Dehydration in alcohols has been reported to effi-
ciently permeabilize thick specimens, thus allowing full
penetration of antibodies or fluorescent probes. For
example, dehydration in methanol followed by rehydra-
tion allowed whole-mount immunostaining of large
insect brains [22] or microvasculature imaging in whole-
mount organs [23]. Moreover, only minimal, and more
importantly isotropic, shrinkage occurs when alcohol
concentration is gradually increased [24]. After simulta-
neous fixation/permeabilization as described above we
then passed the spheroids through a series of baths of
increasing methanol concentration at 4°C (see Methods).
The spheroids were then rehydrated through the same
descending series of baths and resuspended in PBS
before immunostaining.
As can be seen in Figure 1B, this procedure resulted
in a strong and uniform membrane staining with an
anti-EpCAM antibody in both HT29 and CT320X6
spheroids. The same staining pattern was observed at
40 μma n d7 0μm depth, thus demonstrating the full
penetration of the antibody down to the center of the
spheroids. The dramatic increase in permeability
observed after methanol treatment likely results from
two effects. Indeed, methanol is both a strong permeabi-
lizing agent which ‘dissolves’ the membranes more
efficiently than nonionic detergents like Triton X100
and a coagulative fixative [25] which probably makes the
cytosol matrix less gelatinous and thus more permeable
to antibodies. However, a simplified procedure consist-
ing in a single step of fixation/permeabilization in cold
methanol or methanol/acetone without prior aldehydic
fixation led to a massive delocalization of membrane
proteins (data not shown). This is in contrast with a
previous work reporting the successful fixation and per-
meabilization of embryoid bodies by cold methanol/
acetone treatment without observation of membrane
damage [26]. Antigen delocalization is a known possible
artefact in immunostaining experiments [27,28]. It can
occur during the fixation and/or permeabilization steps
and lead to a wrong conclusion regarding the subcellu-
lar localization of the labelled proteins. In the current
study, we found that aldehydic fixation before methanol
treatment allowed EpCAM to be correctly localized at
the plasma membrane. This was also the case for all
antigens examined (see below) whatever the subcellular
location (cytosolic, nuclear, cytoskeleton- and mem-
brane-associated proteins). Nevertheless the possibility
of this artefact should be kept in mind when addressing
a new target since it is dependent of both the tissue and
the antigen examined. It is also noteworthy that,
although the present protocol implies long processing
times, it can be performed in several steps. In particular,
after dehydration/rehydration in methanol, spheroids
could be stored for up to one month at 4°C in PBS
without any alteration in the staining pattern of the
antigens examined. This protocol was used in all subse-
quent immunostaining experiments.
To further validate our protocol, in situ expression of
other proteins was studied and compared to the expres-
sion profiles obtained by FC or paraffin immunochemis-
try (pIHC). We selected several antigens for their
different subcellular distribution (cytoplasm and/or
nucleus and/or plasma membrane) and their relevance
in the field of colon cancer.
Cytokeratin 20 (CK20) is an intermediate filament
protein whose presence is essentially restricted to differ-
entiated cells from gastric and intestinal epithelium and
urothelium [29]. CK20 is routinely used in combination
with CK7 in distinguishing colon carcinomas (CK20
+)
from ovarian, pulmonary and breast carcinoma [30].
Both HT29 and CT320X6 spheroids are formed with
well-differentiated human colon adenocarcinoma cell
lines and cultured in serum-containing medium. The
CK20 expression profile observed here is consequently
in agreement with these data. Indeed, almost all cells in
HT29 and CT320X6 spheroids were found positive in
confocal imaging and also FC analysis (Figure 2).
The cytosolic carbohydrate antigen CA 19-9 is a
glycoprotein related to the monosyalilated Lewis
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the cytosol of human colorectal carcinoma as well as in
the normal mucosa [31]. CA 19-9 is frequently used as
a tumour marker, particularly for colon and pancreas
cancer and CA 19-9 serum level is considered a reliable
indicator for patient follow-up [32]. The three immu-
nostaining techniques revealed both CA 19-9 positive
and negative cell populations within HT29 spheroids
(Figure 3). However, these techniques were not quanti-
tatively equivalent even when the same antibody was
used. Unsurprisingly, FC was the most sensitive techni-
que with 75 ± 2.6% CA 19-9 positive cells detected
while confocal microscopy (62 ± 6.1%) turned out
to have a higher sensitivity than pIHC (51 ± 0.6%,
p < 0.05). Besides, the location pattern of CA 19-9 was
qualitatively similar in confocal imaging (Figure 3A) and
in pIHC (Figure 3C), thus confirming the validity of our
protocol for this marker.
b-catenin plays a dual role in cells as a structural
component of cell-cell adherens junctions and as a key
player in the Wnt signalling pathway [33]. This pivotal
protein thus displays a complex localization pattern,
being present at the plasma membrane (associated with
E-cadherin), the cytosol (within a multiprotein complex
Figure 2 CK20 expression in colon cancer spheroids. (A) CT320X6 (upper panel) and HT29 (lower panel) spheroids were immunostained
against CK20 (yellow) and nuclei were counterstained with TOPRO-3 (cyan). Acquisitions were taken at 70 μm depth. Almost all cells were
positive (scale bar = 50 μm). (B) Permeabilized cells from dissociated CT320X6 (upper panel) and HT29 (lower panel) spheroids were labelled
with the same mAb against CK20. FC analysis confirmed a population with almost 100% of positive cells.
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nucleus (where it acts as a co-transcriptional activator
of target genes and promotes tumour progression). The
nuclear accumulation of the b-catenin is considered the
initial step in colon carcinogenesis and the transcription
of b-catenin target genes becomes constitutively acti-
vated in APC-deficient colon cancers [34]. However,
most tumours do not display a homogeneous subcellular
expression pattern but a nuclear accumulation of b-cate-
nin predominantly localized at the tumour’sp e r i p h e r y
[35]. All cells from HT29, an APC-deficient cell line,
were positive for b-catenin, as illustrated by FC analysis
(Figure 3B). This was confirmed by confocal microscopy
(Figure 3A) which gave additional information about the
subcellular distribution of the protein. Besides being
strongly expressed at the level of the plasma membrane,
soluble b-catenin was often found in cytosolic and
nuclear compartments in confocal images, as confirmed
by pIHC (Figure 3C). This nuclear expression was ran-
domly detected within the spheroids. More recently,
nuclear b-catenin has been also presumed to mark
colon cancer stem cells [13,36,37].
Because they are suspected to play a crucial role in the
initial steps of tumorigenesis, cancer stem cells are the
Figure 3 CA 19-9 and b-catenin expression in HT29 spheroids. (A) HT29 spheroids were immunostained against CA 19-9 (red, upper panel)
or b-catenin (red, lower panel) and nuclei were counterstained with TOPRO-3 (blue). Acquisitions were taken at 70 μm depth. HT29 spheroids
displayed a heterogeneous CA 19-9 expression with a subpopulation of 28% of CA 19-9 negative cells while cytoplasmic, nuclear and membrane
associated b-catenin was found in virtually all cells. White arrowheads show nuclear b-catenin immunostain. Scale bar = 50 μm (whole spheroid)
and 25 μm (zooms). (B) Permeabilized cells from dissociated HT29 spheroids were labelled against CA 19-9 (upper histogram) or b-catenin (lower
histogram) and analysed by flow cytometry. All HT29 spheroid cells were positive for b-catenin whereas 26% of cells were negative for CA 19-9.
(C) HT29 spheroids were embedded using the Cytoblock method and stained with the anti-CA 19-9 antibody (upper image) or the anti-b-
catenin antibody (lower image) using conventional immunohistochemistry and counterstained with hematoxilin. A subset of cells did not
express CA 19-9 (49%) while b-catenin staining was observed in nearly all cells, mainly associated with plasma membrane but also within
cytoplasm and nuclei.
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spheres (including colon cancer spheres, mammospheres
or neurospheres) have been described as being valuable
models for in vitro CSC expansion and are topologically
similar to the spheroids used in the present study. The
expression of specific CSC markers within these micro-
spheres is traditionally investigated by FC after
enzymatic dissociation. This is a powerful approach
allowing to rapidly and quantitatively assess the
presence of CSCs in the spheres and also to isolate
CSCs which can then be tested for in vivo tumourigeni-
city. However, it can not address the precise distribution
of CSC markers within the spheres, for example in
clustered or isolated cells.
We applied the method described in the present work
to study the localization of putative CSC marker-expres-
sing cells within HT29 and CT320X6 spheroids. It has
to be noted that the liquid overlay technique in
conventional culture medium used here is not a method
dedicated to CSC expansion. However, this technique
allows the obtaining of reproducible and compact cancer
cell spheroids, mimicking strong cell-cell interactions
occurring in CSC spheres. First, CD44, a widely distrib-
uted transmembrane cell adhesion molecule and the
major cell surface receptor for hyaluronic acid, is
reported for isolating colorectal cancer initiating cells
[38-40]. Confocal imaging, FC and pIHC studies
revealed that all cells within HT29 spheroids displayed
CD44 expression (Figure 4). These results are in line
with previous phenotyping of HT29 cells [41]. ALDH1,
largely reported as breast CSC marker [42,43], is also a
potential stem cell marker for colon cancer [44,45]. In
the present study, a large population of ALDH1
+
cells has been detected within HT29 spheroids both in
confocal imaging (86% ± 2) and with pIHC (85% ± 3)
(Figure 4). These data are consistent with strong
Figure 4 CD44 and ALDH1 expression in HT29 spheroids. (A) HT29 spheroids were immunostained against CD44 (yellow, upper panel) or
ALDH1 (yellow, lower panel) and nuclei were counterstained with TOPRO-3 (cyan). Acquisitions were taken at 70 μm depth (scale bar = 50 μm).
All cells expressed CD44 while a large population of cells (86%) displayed ALDH1 staining. (B) Conventional pIHC using Cytoblock embedding
technique confirmed that all cells were CD44
+ and 85% were ALDH1
+. (C) All cells from dissociated HT29 spheroids were found CD44
+ in FC
analysis.
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of colon adenocarcinoma, while only few cells were
found in FC assays to display ALDH enzymatic activity,
a potential characteristic of CSCs [44].
CD133 (prominin-1) is a five-transmembrane domain
glycoprotein localized in membrane protrusions. It is
suspected to be a CSC marker in brain [9,46] or colon
[12,47] tumours, although this view has been challenged
[48,49]. FC analysis (Figure 5B) showed that about
5.0% ± 0.4 of the cells were CD133 positive in CT320X6
spheroids. This percentage was close to 1.1% (n = 2) in
HT29 spheroids, a value consistent with a previous
report in HT29 cells [50]. Confocal microscopy also
identified a small fraction of CD133 positive cells in
CT320X6 and HT29 spheroids (Figure 5A) and double
staining experiments additionally revealed that CD133
was colocalized with EBP50, a protein found at the api-
cal membrane of polarized epithelia and involved in
microvilli formation [51]. At high magnification, EBP50
staining also revealed the presence of glandular acini
filled with CD133 positive material. Interestingly, a simi-
lar observation was made recently in human colorectal
cancer where CD133 was found at the glandular-luminal
surface of cancerous cells and in shed cellular debris
inside the glandular lumina [52]. Our method is there-
fore able to reveal fine features in the distribution of
specific markers, even with a very low expression,
throughout the entire spheroids.
Conclusion
Different methods have been reported to study protein
expression within tumour spheres. Immunostaining
detected by peroxidase or fluorophore-conjugated anti-
bodies has been traditionally performed using cytospin
preparations [14,15], paraffin sections [16,17] or frozen
sections [13,17]. Nevertheless, cytospin slides allow
Figure 5 CD133 expression at the luminal surface of some epithelial tumour glands with shedding into the lumina within tumour
spheroids. (A) CD133 (yellow) and EBP50 (magenta) were visualized within CT320X6 (upper panel) and HT29 (lower panel) spheroids by
immunofluorescence staining. Spheroids were counterstained with TOPRO-3 (cyan). CD133 was found into the lumina and colocalized with
EBP50 at the luminal surface of some acini. Acquisitions were taken at 70 μm depth (scale bar = 50 μm). (B) Dissociated cells from CT320X6
(upper histogram) and HT29 (lower histogram) spheroids were similarly labelled against CD133 and analysed by flow cytometry.
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fin and frozen sections do not permit in situ visualiza-
tion of the target protein in the entire structure.
We have developed a protocol allowing successful
antibody penetration in tumour spheres of 150 μmi n
diameter with excellent preservation of the structure
and without artefactual delocalization of the proteins
examined. This allowed us to perform whole mount
immunostaining of these compact structures and to use
the optical sectioning capability of confocal microscopy
to analyse the distribution of several proteins of interest
in the entire spheroids. Besides, 3D localization of the
antigens of interest can be easily obtained from a z-ser-
ies of confocal images collected through the spheroid
(see Additional File 2). Our method is simple, has a
high sensitivity and offers the possibility to screen the
whole structure. It also makes multi-staining and colo-
calization of several antigens possible. Therefore, it
should prove useful as a new tool to image the subcellu-
lar distribution of relevant markers or to localize rare
positive cells, like CSCs, within tumour spheres.
Additional file 1: Unsuccessful protocols for whole-mount staining
of tumour spheroids. CT320X6 spheroids were labelled using a FITC-
conjugated EpCAM antibody (yellow) and counterstained with TOPRO-3
(cyan) after fixation/permeabilization according to one of the protocols
described below. Images were recorded at a depth of 40 μm (A, B, C) or
70 μm (D) relative to the coverslip. (A) Fixation in PFA 4% (3 h at 4°C)
followed by permeabilization in Triton X-100 1% (1 h at RT). Antibody
penetration was limited to the first layer of cells (B) Extraction in Triton
X-100 0.1% (5 min at 4°C) followed by fixation in PFA 4% (3 h at 4°C).
Antibody penetrated poorly in the center of the spheroids while cell
membranes were damaged at the periphery. (C-D) Simultaneous fixation/
permeabilization in PFA 4% and Triton X-100 1% (3 h at 4°C). Acquisition
at 40 μm (C) yielded a section with homogeneous staining and good
preservation of the membranes but optical sections at 70 μm depth (D)
showed a poor penetration of the Ab in the center of the spheroids.
Additional file 2: 3D reconstruction from a z-series of confocal
images taken through a spheroid grown from HT29 cells and
immunostained against CA 19-9 (red). Nuclei are counterstained with
TOPRO-3 (blue). Only a half of the spheroid is presented for better clarity.
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